Amgen’s Revenue by Geography (2016-2023)

This statistic highlights Amgen’s Revenue by Geography, split across the the United States and the Rest of the World regions.

Amgen’s Revenue by Geography

(All figures are in billions, except percentages)

Amgen Inc.’s total revenue increased from $6.10 billion in Q3 2020 to $6.32 billion in Q3 2021 indicating a rise of 3.35% on a year-on-year basis. It also grew by 3.36% compared to $6.11 billion earned in Q2 2021.

The major contribution in Q3 2021 of about 72% of the company’s revenue came from the United States and 28% from the Rest of the World

Amgen Inc.’s revenue by Geography is further bifurcated into the following segments:

(All figures are in millions, except percentages)

The COVID-19 pandemic is expected to continue to have, a negative impact on clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business, and results of operations, as shown in the above table, with some products declining from Q3 2020 to Q3 2021.

Amgen Inc.’s total revenue:

• Sales of Enbrel® (etanercept) fell 3% year over year in Q3 2021, owing to lower volume, inventory, and net selling price.
• Prolia sales grew 15% year over year in Q3 2021, owing to a 13% rise in volume. As osteoporosis diagnosis rates in the United States improved, so did the number of new and repeat patient visits.
• Sales of Otezla® (apremilast) climbed by 13% year over year.
• Sales of XGEVA® (denosumab) grew 7% year-on-year basis in Q3 2021, owing to a 9% rise in volume largely offset by a lower net selling price.
• Total sales of established products such as Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim), EPOGEN® (epoetin alfa), Aranesp® (darbepoetin alfa), Parsabiv®, and Sensipar®/MimparaTM decreased by 21% year-on-year basis.
• Repatha sales grew 33% year over year in theQ3 2021, owing to a 42 percent rise in volume offset by a lower net selling price.
• KYPROLIS® (carfilzomib) sales climbed 13% year-on-year basis in Q3 2021, owing to a 10% volume increase fueled by physician adoption of KYPROLIS in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd).
• Corlanor®, GENSENTA, IMLYGIC®, AVSOLA®, Bergamo, and RIABNITM are some of the other brands.
• ENBREL contributed the most income from the United States (28%) and Other products (23%) contributed the second most, and so on.
• The major contribution of the revenue from the Rest of the World of 38% was made by Other products and the second-highest from Prolia® of about 15%Other goods contributed 38% of revenue from the Rest of the World, with Prolia® contributing around 15%.

About the Company

Amgen is dedicated to unleashing the promise of biology for people suffering from devastating illnesses. To unravel the complexity of the disease and comprehend the principles of human biology, this approach starts with advanced human genetics.

On April 8, 1980, venture capitalists William K. (Bill) Bowes and partners launched Amgen (Applied Molecular Genetics Inc.) in Thousand Oaks, California. The company, which employs three people, is housed in a shared building. The company formally changed its name to Amgen, and its first public offering (IPO) on June 17, 1983, raised roughly $40 million under the leadership of CFO Gordon Binder.

Did you like Amgen’s Revenue by Geography statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.